The effect of rosuvastatin treatment on fasting triglyceride levels, non fasting triglyceride levels and hscrp

TThe relationship of hypertriglyceridemia and the risk for coronary heart disease (CHD) has been an issue of great interest and controversy. Hypertriglyceridemia is a heterogeneous disorder and some prospective epidemiological studies have reported a positive relationship between serum fasting triglyceride levels and CHD, however hypertriglyceridemia as an independent risk factor for CHD is still controversial. Hypertriglyceridemia correlates strongly with the presence of small, dense particles of low density lipoprotein (LDL) cholesterol and reductions of high density lipoprotein (HDL) cholesterol, both of which are known to be associated with premature CHD. Previously some prospective studies and case-control studies demonstrated a relationship between nonfasting triglyceride (TG) levels and cardiovascular disease. In this study we aimed to evaluate the effect of rosuvastatin treatment on fasting TG levels, non fasting TG levels and an inflammatory parameter hsCRP. A total of 51 patients who were admitted to our outpatient cardiology clinic were included in the study. Oral lipid loading was used in order to measure postprandial TG (PPTG) levels after 12 hours of fasting state. All subjects received a breakfast consisting 60% of fat, 16.8% of protein and 23.2% of carbohydrates, with a total of 891 kcal. In the fasting state and after the lipid rich breakfast (at 4th hour), triglyceride, LDL cholesterol, HDL cholesterol, total cholesterol and hsCRP levels were measured at beginning and after the one month 10 mg/day rosuvastatin therapy. The mean age of the study population was 54.3 ± 11.6 years and 26 (% 50.9) of them were females. PPTG levels were significant increased after lipid loading according to baseline TG levels. After one month rosuvastatin treatment, fasting TG levels and PPTG levels were significantly decreased according to their baseline levels (respectively 20% and 23.7%). After rosuvastatin therapy, the decreasing at PPTG levels was significantly higher compare to fasting TG levels. hsCRP was significantly decreased PP state after one month treatment compare to beginning postprandial levels. Our data show that after one month rosuvastatin therapy, fasting TG levels and PPTG levels were significantly decreased. Also the decreasing at PPTG levels was significantly higher compare to fasting TG levels after rosuvastatin therapy.